Xvivo Perfusion ABXVIPF -1.32%91 Revenue per Share is $2.82 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $41.68 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 753 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 86.45% on this metric.
Xvivo Perfusion AB's revenue per share for the
three
months ended in Mar. 2026 was $0.82.
Xvivo Perfusion AB's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.82.
Warning Sign:
Xvivo Perfusion AB revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Xvivo Perfusion AB was -2.10% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 22.30% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 34.50% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 18.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Xvivo Perfusion AB's Revenue per Share or its related term are showing as below:
XVIPF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.4 Med: 15.85 Max: 44.8
Current: 22.3
During the past 13 years, Xvivo Perfusion AB's highest 3-Year average Revenue Per Share Growth Rate was 44.80% per year. The lowest was 4.40% per year. And the median was 15.85% per year.
XVIPF's 3-Year Revenue Growth Rate is ranked better than 86.45% of 753
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs XVIPF: 22.30
Xvivo Perfusion AB (OTCPK:XVIPF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Xvivo Perfusion AB Revenue per Share Related Terms
Xvivo Perfusion AB Revenue per Share Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Revenue per Share Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Xvivo Perfusion AB's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Revenue per Share of $2.82 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #102 out of 753 companies in the Medical Devices & Instruments industry, placing it in the top 13.5%.
Is Xvivo Perfusion AB's Revenue per Share too high?
Xvivo Perfusion AB's current Revenue per Share is $2.82. The Medical Devices & Instruments industry median Revenue per Share is 3.70. Xvivo Perfusion AB's value of $2.82 is 23.8% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #102 out of 753 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Revenue per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #102 out of 753 companies for Revenue per Share. This places Xvivo Perfusion AB in the top 14% of its industry — outperforming the majority of peers. The industry median Revenue per Share is 3.70. Xvivo Perfusion AB's value of $2.82 is 23.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 753 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Revenue per Share of $2.82 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Revenue per Share is $2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $41.68, compared to a current price of $29.00 — trading 30.4% below its estimated fair value. The current Revenue per Share is $2.82 and 23.8% below the Medical Devices & Instruments industry median of 3.70. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Revenue per Share is $2.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 30.4% below its estimated GF Value™ of $41.68.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Revenue per Share: $2.82
GF Value™: $41.68 vs. price of $29.00 (30.4% below fair value)
Industry Position: 23.8% below the Medical Devices & Instruments median (#102 of 753)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
